Limited experimental data remains a key challenge in applying machine learning to drug discovery, particularly for cancer-related targets. In this study, we present a data-efficient active meta-deep learning framework to predict mitogen-activated protein kinase 1 (MAPK1) inhibitors, which are promising candidates for cancer-related therapies. Our approach integrates active learning (AL) with a meta-model that combines four deep architectures: a convolutional neural network, an attention, a graph convolutional network, and a graph neural network-attention, trained on molecular descriptors and graph-based representations. These models generate four probability-based features that feed into an attention-based meta-learner, improving predictive performance by 5.12% in the area under the precision-recall curve (AUPRC) and 5.48% in the Matthews correlation coefficient (MCC) using only 10% of the training data. Among the AL sampling strategies evaluated, entropy sampling showed competitive performance in selecting informative molecules for model improvement. Overall, our framework achieves an AUPRC of 0.835 ± 0.017 and MCC of 0.817 ± 0.017, on par with a traditional training method despite using only 26.7% of the training data. Compared to a conventional random forest model trained on brute-force, a 100% full training set, our approach shows a 10.6% improvement in AUPRC and modest gains in MCC, confirming the effectiveness of the proposed framework. Under severe class imbalance, balanced accuracy steadily increased across AL iterations, reaching values greater than 0.85 at the final iteration for all uncertainty-driven strategies. Molecular docking confirmed successful prioritization of the top four predicted compounds. Evaluation on an external MAPK1 data set demonstrated generalizability, with our approach achieving an AUPRC of 0.818 and an MCC of 0.403, comparable to the independent test set. These results highlight the potential of combining intelligent data selection with deep learning architectures through the meta-model to accelerate predictive performance in data-scarce drug discovery. Scientific contribution: This study contributes a novel, data-efficient active meta-deep learning framework for predicting MAPK1 inhibitors, addressing the challenge of limited experimental data in a cancer-specific target. By integrating AL with a meta-model composed of four deep architectures, the approach significantly enhances the predictive performance using only a fraction of the training data. The framework achieves superior metrics compared to traditional training methods, highlighting its potential to accelerate drug discovery in data-scarce settings.
Zetta et al. (Tue,) studied this question.